Chicken Lips
04 May 2018
Re: Fraction and Rounding Down etc Thanks RogerIt seems like a lot of effort for not so much gain.
Roger Baron
04 May 2018
Re: Fraction and Rounding Down etc It shouldn't make any difference to investors unless they have a very small holding and it isn't divisible by 50. The most anyone can lose is £4.99.In theory the day of the change you will have 1/50th of the number of shares and they will be each worth 50 times as much. No change.In my view therefore this is just window dressing.They have given the reasons for doing it so I won't repeat them. Downside is that there will be a cost to the company for implementation, advisers fees etc. I have had shares in a few companies over the years that have done this and I think in every case the company and share price has gone down afterwards! I hope that this is just coincidence and that this will break (my personal) trend. I wonder if anyone has done a study of all companies that have done this? Yours, slightly concerned.
Chicken Lips
04 May 2018
Fraction and Rounding Down etc Read this RNS with interest but I'm not sure the implications are clear, seems on the face of it very positive. But I'm not sure it 'makes the shares more attractive to investors'. Surely that is performance and progress in the technology?Bemused
d gaser
03 May 2018
Kymriah™ FDA clearence Received todays Barclays investment note to find this .BE HAPPYDAVE FTSE :Intraday Wed 2 May 2018(Sharecast News) - Gene and cell therapy group Oxford BioMedica has seen Norvatis' chimeric antigen receptor T cell therapy, Kymriah, gain approval from the US Food and Drug Administration for intravenous infusion for its second indication, providing it with a significant boost.Oxford BioMedica, which has been the sole manufacturer of the lentiviral vector that encodes Kymriah since signing an exclusive agreement with Novartis over the commercial and clinical supply of the product back in July 2017, could potentially receive as much as $100m from the deal over the next three years.Kymriah, the first CAR-T therapy available in the US for two distinct indications in non-Hodgkin lymphoma, had not yeat been looked at for its potential second indicator - the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.As of 1050 BST, Oxford Biomedica shares had gained 1.74% to 12.25p.
SlickNeeson
02 May 2018
OXB Release [link]
d gaser
02 May 2018
Kymriah™ gets FDA clearence for relapsed B Cell Today Novartis have released a RNS regarding suspension for intravenous infusion for its second indication - this is for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphomaBE HAPPYDAVE . Basel, May 1, 2018 - Novartis today announced the US Food and Drug Administration (FDA) has approved Kymriah® (tisagenlecleucel) suspension for intravenous infusion for its second indication - the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma and DLBCL arising from follicular lymphoma. Kymriah is not indicated for the treatment of patients with primary central nervous system lymphoma. Kymriah, developed in collaboration with the University of Pennsylvania, became the first chimeric antigen receptor T cell (CAR-T) therapy to receive regulatory approval in August 2017 for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. Kymriah is now the only CAR-T cell therapy to receive FDA approval for two distinct indications in non-Hodgkin lymphoma (NHL) and B-cell ALL. "Today's FDA approval of Kymriah provides another opportunity for Novartis to build on its leadership in CAR-T development, delivering a potentially transformative therapy with durable and sustained response rates and a well-characterized safety profile to help patients in dire need of new treatment options," said Liz Barrett, CEO, Novartis Oncology. "We look forward to leveraging all of our learnings and new capabilities from the initial launch of Kymriah in pediatric and young adult B-cell ALL for this larger group of patients." DLBCL is the most common form of NHL[2],[3]. For patients who relapse or don't respond to initial therapy, there are limited treatment options that provide durable responses, and median life expectancy is approximately six months[4],[5]. "The goal of Kymriah is to provide physicians with a therapy that has demonstrated durable response rates in relapsed or refractory DLBCL patients, a patient population that has endured multiple rounds of chemotherapy with many having experienced unsuccessful stem cell transplants," said Stephen J. Schuster, MD, the Robert and Margarita Louis-Dreyfus Professor in Chronic Lymphocytic Leukemia and Lymphoma Clinical Care and Research in Penn's Perelman School of Medicine and director of the Lymphoma Program at the Abramson Cancer Center. "With this approval, physicians now have a meaningful therapeutic option that can achieve and maintain a sustained response without stem cell transplant along with a consistent safety profile." Kymriah is an innovative immunocellular therapy that is a one-time treatment manufactured individually for each patient using the patient's own T cells. Kymriah uses the 4-1BB costimulatory domain in its chimeric antigen receptor to enhance cellular expansion and persistence. In 2012, Novartis and Penn entered into a global collaboration to further research, develop and commercialize CAR-T cell therapies, including Kymriah, for the investigational treatment of cancers. As part of the Novartis commitment to ensure eligible patients have access to Kymriah, the company continues to collaborate with the Centers for Medicare and Medicaid Services (CMS) on the creation of an appropriate value-based pricing approach. Novartis continues to be an innovator and leader in value and innovative-based pricing options, and is proud to work with CMS and other stakeholders across the healthcare spectrum on creating a sustainable and modern healthcare payment system. To ensure all hospitals and their associated clinics are aware of how to manage the risks of cytokine release syndrome (CRS) and neurological toxicities, Kymriah is available through a Risk Evaluation and Mitigation Strategy (REMS) pro
green.as1953
02 May 2018
RNS As Expected.
luguvalium
01 May 2018
Re: Peter Gabriel's wife Hard on the heals of the successful treatment of PG's wife there is an RNS from Novartis to confirm FDA acceptance of Kymriah for usage in a large B-cell lymphoma. It is now the only CAR-T therapy approved for two distinct indications in non-Hodgkin lymphoma (NHL) and B-cell ALL. There may well be an OXB RNS in the morning to confirm.
luguvalium
29 Apr 2018
Peter Gabriel's wife Good news from a human interest perspective in that PG' s wife has made a remarkable recovery from an aggressive form of non-hodgins lymphoma but also thanks to the use of CAR T-cell therapy. Once again this puts OXB on the map in terms of its ability to programme the T cell with its lentivirus vector (and of course companies like Novartis)
mol42
29 Apr 2018
Cell and Gene Therapy 17 04 18 Jason Slingsby[link]
Fishnthenet
26 Apr 2018
Re: Chairman buys 22.015 shares on the open... DaveThink you will find that he buys every month as he does not receive salary but shares instead on open market.
d gaser
25 Apr 2018
Chairman buys 22.015 shares on the open market Dr Lorenzo Tallarigo, Chairman, bought 22,015 shares in the company on the 23rd April 2018 at a price of 12.00p. The Director now holds 2,263,270 shares.BE HAPPYDAVE
d gaser
11 Apr 2018
third dirctor buys 1m share's on the open market Obviously I'm very pleased to see another director buying shares on the open market ,(that's 3 now ) as it shows they have confidence in OXB future,this combined show of confidence in OXB future will hopefully see the S/P move north again, it could also be the prelude to some thing very big. BE HAPPYDAVE .Director Dealings / Market Share Purchase Oxford, UK - 11 April 2018: Oxford BioMedica plc ("Oxford BioMedica" or "the Group"
(LSE: OXB), a leading gene and cell therapy group, today announces that Vulpes Testudo Fund, a person closely associated with Martin Diggle, Non-Executive Director, has purchased 1,000,000 ordinary shares of 1p each ("Ordinary Shares" in the Company on 10 April 2018 on the London Stock Exchange at a price of 11.0p per share. Following this purchase Vulpes Testudo/Vulpes Life Sciences Fund holds 582,008,434 ordinary shares representing 17.7% of the Company. The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares purchased.
d gaser
09 Apr 2018
Another dirctor buys ,67,646 shares on open mark... I wonder if there is good news on the way? as this is the second director to buy on shares on the open market in less than a week Keeping my fingers crossed .Oxford, UK - 09 April 2018: Oxford BioMedica plc ("Oxford BioMedica" or "the Group" (LSE: OXB), a leading gene and cell therapy group, today announces that Stuart Paynter, Chief Financial Officer has purchased 87,626 ordinary shares of 1p each ("Ordinary Shares" in the Company on 09 April 2018 on the London Stock Exchange at a price of 11.2p per share. Following this purchase Stuart Paynter holds 87,626 ordinary shares representing 0.003% of the Company. BE Happy Dave D>
d gaser
05 Apr 2018
dirctor buys 371,450 shares on open market It's nice to see directors buying on the open market like this .BE HAPPYDAVE Oxford, UK - 05 April 2018: Oxford BioMedica plc ("Oxford BioMedica" or "the Group" (LSE: OXB), a leading gene and cell therapy group, was informed that on 05 April 2018 Peter Nolan, Chief Business Officer acquired ordinary shares of 1p each ("Ordinary Shares" in the Company for his wife and himself as follows: Peter NolanDirector / PDMRTitle Chief Business OfficerPrice per share (p)10.8pNumber of Ordinary Shares acquired 371,450Number of Ordinary Shares owned 2,289,771 Interest after purchase 0.07%% of total issued share capital
